Objective: This study evaluated the differences between IDH1-R132H and CD133 expression in different categories of astrocytoma. Material and methods: This study used a cross-sectional design. Sixty-seven paraffin embedded block of Diffuse Astrocytoma (DA), Anaplastic Astrocytoma (AA) and Glioblastoma (GB) were assessed using using the monoclonal antibody IDH1-R132H and Rabbit polyclonal antibody CD133. Results: It was found that there was a significant relationship between the expression of IDH1-R132H and CD133 in DA, AA and GB (p<0.001). Astrocytoma with IDH-mutant molecular status will express more markers of cancer stem cell CD133 than IDH-wildtype. Conclusion: The IDH1-R132H and CD133 can provide predictive value on treatment success, disease prognosis, recurrence and can be considered as target combination therapy with chemotherapy.
Sabunga, O. Desty , Kaelan, C. , Zainuddin, A. Alfian , Sungowati, N. Ketut , Cangara, M. H. and Miskad, U. (2022). Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma. Asian Pacific Journal of Cancer Prevention, 23(9), 3051-3059. doi: 10.31557/APJCP.2022.23.9.3051
MLA
Sabunga, O. Desty, , Kaelan, C. , , Zainuddin, A. Alfian, , Sungowati, N. Ketut, , Cangara, M. H. , and Miskad, U. . "Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma", Asian Pacific Journal of Cancer Prevention, 23, 9, 2022, 3051-3059. doi: 10.31557/APJCP.2022.23.9.3051
HARVARD
Sabunga, O. Desty, Kaelan, C., Zainuddin, A. Alfian, Sungowati, N. Ketut, Cangara, M. H., Miskad, U. (2022). 'Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma', Asian Pacific Journal of Cancer Prevention, 23(9), pp. 3051-3059. doi: 10.31557/APJCP.2022.23.9.3051
CHICAGO
O. Desty Sabunga , C. Kaelan , A. Alfian Zainuddin , N. Ketut Sungowati , M. H. Cangara and U. Miskad, "Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma," Asian Pacific Journal of Cancer Prevention, 23 9 (2022): 3051-3059, doi: 10.31557/APJCP.2022.23.9.3051
VANCOUVER
Sabunga, O. Desty, Kaelan, C., Zainuddin, A. Alfian, Sungowati, N. Ketut, Cangara, M. H., Miskad, U. Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma. Asian Pacific Journal of Cancer Prevention, 2022; 23(9): 3051-3059. doi: 10.31557/APJCP.2022.23.9.3051
)